Jay Hubsher, MD
Nephrology · Darby, PANPI 1942289269
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,600 of the $30,907 with a category attached, or 73.1%. Amgen accounts for 88.7% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $13,938 and has fallen 95.0% since, to $694 in 2025. Among nephrology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 199 payments — averaging $155.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$27K
- Vifor Pharma, Inc.$797
- AstraZeneca$709
- Novo Nordisk$219
- Fresenius USA Marketing, Inc.$175
- Boehringer Ingelheim$164
- plus $1K from 18 others
Across 1 payment — averaging $8274.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$8K
What the payments were for
- Speaking & faculty fees$22,60073%
- Travel & lodging$3,05710%
- Food & beverage$5,25017%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 69 | $27,425 |
| Vifor Pharma, Inc. | 28 | $797 |
| AstraZeneca(2 entities) | 30 | $709 |
| Novo Nordisk | 7 | $219 |
| Fresenius USA Marketing, Inc. | 8 | $175 |
| Boehringer Ingelheim | 6 | $164 |
| Bayer | 6 | $153 |
| Calliditas Therapeutics US Inc. | 3 | $152 |
| Otsuka America Pharmaceutical, Inc. | 9 | $151 |
| Ardelyx, Inc. | 6 | $134 |
| Vantive US Healthcare LLC | 1 | $128 |
| Baxter Healthcare | 1 | $118 |
| ANI Pharmaceuticals, Inc. | 5 | $115 |
| Travere Therapeutics, Inc. | 3 | $77 |
| OPKO Pharmaceuticals, LLC | 3 | $76 |
| Mallinckrodt Enterprises LLC | 3 | $70 |
| Novartis | 2 | $55 |
| Mallinckrodt Hospital Products Inc. | 2 | $51 |
| GSK | 2 | $30 |
| Aurinia Pharma U.S., Inc. | 1 | $27 |
| Sanofi | 1 | $24 |
| Akebia Therapeutics Inc | 1 | $22 |
| Outset Medical Inc | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Parsabiv$26,220
- Renal - Chronic$128
- Veltassa$114
- LOKELMA$106
How this compares
$30,907 in reported general payments places this provider in the 95th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 180 | $189,785 |
| JardianceEmpagliflozin | 115 | $114,464 |
| Sevelamer Carbonate | 47 | $20,759 |
| LokelmaSodium Zirconium Cyclosilicate | 28 | $20,511 |
| Lanthanum Carbonate | 15 | $13,110 |
| Cinacalcet Hcl | 19 | $12,024 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $9,826 |
| Calcium Acetate | 50 | $2,999 |
| Calcitriol | 99 | $2,232 |
| Clonidine | 14 | $1,452 |
| Potassium Chloride | 53 | $1,185 |
| Losartan Potassium | 90 | $1,151 |
| Lisinopril | 144 | $1,140 |
| Allopurinol | 81 | $872 |
| Furosemide | 149 | $815 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $709 | $210,296208 claims |
| Boehringer IngelheimJardiance | $164 | $114,464115 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $115 | $72140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 nephrology providers in Pennsylvania.
Other nephrology in Darby
- Nelson KopytAllentown$949K
- Christopher GislerPittsburgh$757K
- Rakesh GulatiPhiladelphia$657K
- Raymond TownsendPhiladelphia$357K
- Prince AnandDanville$331K
- Ellie KelepourisPhiladelphia$287K
- Jonathan DiamondHarrisburg$249K
- Abdallahsassine GearaPhiladelphia$225K
- Khaled NasharPittsburgh$198K
- Katalin SusztakPhiladelphia$192K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.